9 August 2024 - US FDA requests additional Phase 3 study.

Lykos Therapeutics announced that the US FDA has issued a complete response letter for the new drug application for midomafetamine capsules for the treatment of post-traumatic stress disorder in adults.

Read Lykos Therapeutics press release